B Helbling
Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland
Overbeck K, Rickenbach M, Cerny A, Moradpur D, Heim M, Malinverni R, Borovicka J, Helbling B, Mullhaupt B, Dufour J, Negro F. Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland. Swiss Med Wkly 2010
03.02.2010Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in Switzerland
03.02.2010Swiss Med Wkly 2010
Overbeck K, Rickenbach M, Cerny A, Moradpur D, Heim M, Malinverni R, Borovicka Jan, Helbling B, Mullhaupt B, Dufour J F, Negro F
Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection
Helbling B, Mullhaupt B, Renner E, Rickenbach M, Bucher S, Negro F, Cerny A, Heim M, Borovicka J, Dufour J, Malinverni R, Gonvers J, Overbeck K, Swiss Hepatitis C Cohort Study. Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008; 57:1597-603.
01.11.2008Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection
01.11.2008Gut 2008; 57:1597-603
Helbling B, Mullhaupt B, Renner E L, Rickenbach M, Bucher S, Negro F, Cerny A, Heim M, Borovicka Jan, Dufour J-F, Malinverni R, Gonvers J-J, Overbeck K, Swiss Hepatitis C Cohort Study
Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
Meyer-Wyss B, Renner E, Arn M, Meyenberger C, Borovicka J, Rossi L, Criblez D, Oneta C, Gonvers J, Rammert C, Mullhaupt B, Helbling B, Egger H, Rich P, Swiss Association for the Study of the Liver (SASL). Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. Journal of viral hepatitis 2006; 13:457-65.
01.07.2006Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis
01.07.2006Journal of viral hepatitis 2006; 13:457-65
Meyer-Wyss B, Renner E L, Arn M, Meyenberger Christa, Borovicka Jan, Rossi L, Criblez D, Oneta C, Gonvers J-J, Rammert C, Mullhaupt B, Helbling B, Egger Hp, Rich P, Swiss Association for the Study of the Liver (SASL)